{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:34:09Z","timestamp":1791092049769,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.addr.2009.06.004","type":"journal-article","created":{"date-parts":[[2009,8,10]],"date-time":"2009-08-10T05:13:53Z","timestamp":1249881233000},"page":"1214-1219","source":"Crossref","is-referenced-by-count":160,"title":["ProLindac\u2122 (AP5346): A review of the development of an HPMA DACH platinum Polymer Therapeutic"],"prefix":"10.1016","volume":"61","author":[{"given":"David P","family":"Nowotnik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Cvitkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2009.06.004_bib1","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/205698a0","article-title":"Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode","volume":"205","author":"Rosenberg","year":"1965","journal-title":"Nature"},{"key":"10.1016\/j.addr.2009.06.004_bib2","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(02)00733-7","article-title":"Scientists and clinicians test their metal\u2212back to the future with platinum compounds","volume":"3","author":"Guminski","year":"2002","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.addr.2009.06.004_bib3","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2174\/138161209787582183","article-title":"Metal complexes, their cellular targets and potential for cancer therapy","volume":"15","author":"Chen","year":"2009","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.addr.2009.06.004_bib4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2217\/14796694.5.1.33","article-title":"New-generation platinum agents for solid tumors","author":"Shah","year":"2009","journal-title":"Future Oncol."},{"key":"10.1016\/j.addr.2009.06.004_bib5","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1158\/1078-0432.CCR-07-2176","article-title":"Current status and future prospects for satraplatin, an oral platinum analogue","volume":"14","author":"Choy","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2009.06.004_bib6","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1517\/13543784.16.7.1009","article-title":"Broadening the clinical use of platinum drug-based chemotherapy with new analogues: Satraplatin and picoplatin","volume":"16","author":"Kelland","year":"2007","journal-title":"Expert Opin. Investig. Drugs Jul."},{"key":"10.1016\/j.addr.2009.06.004_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1023\/A:1008215213739","article-title":"Carboplatin versus cisplatin in solid tumors: An analysis of the literature","volume":"9","author":"Lokich","year":"1998","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.addr.2009.06.004_bib8","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.2165\/00003495-200363190-00013","article-title":"Oxaliplatin \u2212 a review of its use in combination therapy for advanced metastatic colorectal cancer","volume":"63","author":"Simpson","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2009.06.004_bib9","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/sj.ki.5002786","article-title":"Cisplatin nephrotoxicity: mechanisms and renoprotective strategies","volume":"73","author":"Pabla","year":"2008","journal-title":"Kidney Int."},{"key":"10.1016\/j.addr.2009.06.004_bib10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2165\/00003088-199733030-00002","article-title":"Clinical pharmacokinetics and dose optimisation of carboplatin","volume":"33","author":"Duffull","year":"1997","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.addr.2009.06.004_bib11","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/WCO.0b013e3282f1a06e","article-title":"Neurologic complications of chemotherapy agents","volume":"20","author":"Kannarkat","year":"2007","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.addr.2009.06.004_bib12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.critrevonc.2006.01.001","article-title":"Oxaliplatin-related neurotoxicity: how and why?","volume":"59","author":"Pasetto","year":"2006","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.addr.2009.06.004_bib13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2165\/00003495-200059004-00002","article-title":"Clinical perspectives on platinum resistance","volume":"59","author":"Giaccone","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.addr.2009.06.004_bib14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0010-8545(97)00023-4","article-title":"The influence of structure on the activity and toxicity of Pt anticancer drugs","volume":"166","author":"Hambley","year":"1997","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.addr.2009.06.004_bib15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.critrevonc.2004.08.008","article-title":"Recognition and processing of cisplatin- and oxaliplatin-DNA adducts","volume":"53","author":"Chaney","year":"2005","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"10.1016\/j.addr.2009.06.004_bib16","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1023\/A:1008213732429","article-title":"Oxaliplatin: a review of preclinical and clinical studies","volume":"9","author":"Raymond","year":"1998","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.addr.2009.06.004_bib17","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1146\/annurev.med.59.061506.185523","article-title":"Nanotechnology and cancer","volume":"59","author":"Heath","year":"2008","journal-title":"Annual Rev. Med."},{"key":"10.1016\/j.addr.2009.06.004_bib18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ejpb.2008.11.010","article-title":"Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect","volume":"71","author":"Maeda","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2009.06.004_bib19","article-title":"Polymeric drug delivery of platinum-based anticancer agents","author":"Haxton","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2009.06.004_bib20","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/S0959-8049(99)00030-1","article-title":"HPMA copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity in vivo","volume":"35","author":"Gianasi","year":"1999","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.addr.2009.06.004_bib21","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/1061186021000072456","article-title":"HPMA copolymers platinates containing dicarboxylato ligands. Preparation, characterisation and in vitro and in vivo evaluation","volume":"10","author":"Gianasi","year":"2002","journal-title":"J. Drug Target."},{"key":"10.1016\/j.addr.2009.06.004_bib22","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ejca.2003.09.022","article-title":"Improved targeting of platinum chemotherapeutics. The antitumour activity of the HPMA copolymer platinum agent AP5280 in murine tumour models","volume":"40","author":"Lin","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.addr.2009.06.004_bib23","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1081\/DDC-120025455","article-title":"Pharmaceutical development of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum anticancer agent AP 5280","volume":"29","author":"Bouma","year":"2003","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.addr.2009.06.004_bib24","first-page":"198","article-title":"Pharmaceutical quality control of the investigational polymer-conjugated platinum anticancer agent AP 5280","volume":"57","author":"Bouma","year":"2003","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"10.1016\/j.addr.2009.06.004_bib25","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/00001813-200210000-00003","article-title":"Stability and compatibility of the investigational polymer-conjugated platinum anticancer agent AP 5280 in infusion systems and its hemolytic potential","volume":"13","author":"Bouma","year":"2002","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.addr.2009.06.004_bib26","unstructured":"M.M. Tibben, J.M. Rademaker-Lakhai, J.R. Rice, D.R. Stewart, J.H. Schellens, J.H. Beijnen"},{"key":"10.1016\/j.addr.2009.06.004_bib27","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00216-002-1340-9","article-title":"Determination of total platinum in plasma and plasma ultrafiltrate, from subjects dosed with the platinum-containing N-(2-hydroxypropyl)methacrylamide copolymer AP5280, by use of graphite-furnace Zeeman atomic-absorption spectrometry","volume":"373","year":"2002","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.addr.2009.06.004_bib28","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1158\/1078-0432.CCR-03-0315","article-title":"A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3weeks in patients with solid tumors","volume":"10","author":"Rademaker-Lakhai","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2009.06.004_bib29","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1158\/1078-0432.CCR-05-2169","article-title":"Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system","volume":"12","author":"Rice","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2009.06.004_bib30","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1021\/bc0600517","article-title":"Synthesis and characterization of AP5346, a novel polymer-linked diaminocyclohexyl platinum chemotherapeutic agent","volume":"17","author":"Sood","year":"2006","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2009.06.004_bib31","first-page":"835","article-title":"Pharmaceutical development, quality control, stability and compatibility of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum antineoplastic agent AP5346","volume":"61","author":"Van der Schoot","year":"2006","journal-title":"Pharmazie."},{"key":"10.1016\/j.addr.2009.06.004_bib32","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ejps.2006.03.001","article-title":"Oxaliplatin degradation in the presence of important biological sulphur-containing compounds and plasma ultrafiltrate","volume":"28","author":"Jerremalm","year":"2006","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2009.06.004_bib33","series-title":"Platinum release characteristics of ProLindac\u2122 (AP5346), poster presentation at the 10th International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy","author":"Sood","year":"2007"},{"key":"10.1016\/j.addr.2009.06.004_bib34","unstructured":"Lokiec Geneva poster. Ex vivo plasma protein binding and in vitro evaluations of AP5346, a novel platinum-bound biopolymer: evidence showing that \u226572hr DACH-platinum release may play a major role in cytotoxicity."},{"key":"10.1016\/j.addr.2009.06.004_bib35","series-title":"Presented at the 10th International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy, Verona, Italy","article-title":"Antiproliferative effects of ProLindac, a novel DACH-platinum linked polymer compound, as a single agent and in combination with other anticancer drugs in a panel of human cancer cell lines","author":"Serova","year":"2007"},{"key":"10.1016\/j.addr.2009.06.004_bib36","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00280-006-0397-0","article-title":"Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4weeks to advanced solid tumor patients","volume":"60","author":"Campone","year":"2007","journal-title":"Cancer Chemother. Pharmacol."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X09002440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X09002440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T10:18:57Z","timestamp":1633774737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X09002440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":36,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S0169409X09002440"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2009.06.004","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}